Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | CASP7 | P55210 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10654293 | 0.90 | ALDH1A1 (0.70) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL516379 | 0.86 | POLB (1.00) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL21765989 | 0.86 | POLB (0.77) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL3455612 | 0.84 | POLB (0.75) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL22521846 | 0.84 | ALDH1A1 (1.00) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL8664913 | 0.84 | POLB (0.75) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL10421944 | 0.84 | POLB (0.75) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL9406540 | 0.83 | POLB (0.83) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| Hydrochloric Acid SCHEMBL8668067 | 0.83 | POLB (0.73) | POLBALDH1A1CYP3A4HSD17B10CASP1 | |
| SCHEMBL515773 | 0.82 | POLB (0.77) | POLBALDH1A1CYP3A4HSD17B10CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280040-A1 | SYNTHESIS AND PHARMACOKINETIC ACTIVITIES OF PULMODIL AND PULMODIL-1, TWO CHLOROPHENYLPIPERAZINE SALT DERIVATIVES | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-04 | — | — | US | claimed |
| EP-1466589-B1 | Stable cosmetic composition comprising a fatty acid glyceride, an alcohol and a silicone emulsifier | OREAL (FR) | 2008-12-17 | — | — | EP | claimed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| US-20190110977-A1 | PROCESS FOR TREATMENT OF KERATINOUS MATERIALS AND KIT FOR FORMULATION OF A COSMETIC PRODUCT | L'OREAL (FR) | 2019-04-18 | — | — | US | disclosed |
| EP-2992885-A2 | METHOD FOR INHIBITING A LIVER DISEASE | Jansfat Biotechnology Co., Ltd. (TW) | 2016-03-09 | — | — | EP | disclosed |
| CN-105380949-A | Composition for treating high fat food induced liver lipopexia | JANSFAT BIOTECHNOLOGY CO LTD | 2016-03-09 | — | — | CN | disclosed |
| US-20150359901-A1 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY | JANSFAT BIOTECHNOLOGY CO., LTD. (TW) | 2015-12-17 | — | — | US | disclosed |
| US-20150359798-A1 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY | JANSFAT BIOTECHNOLOGY CO., LTD. (TW) | 2015-12-17 | — | — | US | disclosed |
| CN-102973566-B | DPAs and high molecular polymer for hyperlipemia and reducing food intake amount and adipose tissue weight of obese animals | CHEN YINGJUN (CN) | 2015-10-07 | — | — | CN | disclosed |
| US-20150174157-A1 | INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-06-25 | — | — | US | disclosed |
| US-20100280040-A1 | SYNTHESIS AND PHARMACOKINETIC ACTIVITIES OF PULMODIL AND PULMODIL-1, TWO CHLOROPHENYLPIPERAZINE SALT DERIVATIVES | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-04 | — | — | US | disclosed |
| US-20100280041-A1 | RHOKINASE-DEPENDENT INHIBITION ACTIVITY ON PULMONARY ARTERY ENDOTHELIUM DYSFUNCTION, MEDIAL WALL THICKNESS AND VASCULAR OBSTRUCTION OF PULMODIL AND PULMODIL-1 | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-04 | — | — | US | disclosed |
| WO-2009098139-A1 | COSMETIC COMPOSITION CONTAINING A DIBENZOYLMETHANE DERIVATIVE AND A PARTICULAR NEUTRAL N-ACYLAMINO ACID ESTER DERIVATIVE; PROCESS FOR PHOTOSTABILIZING THE DIBENZOYLMETHANE DERIVATIVE | L'OREAL (FR) | 2009-08-13 | — | — | WO | disclosed |
| US-20080159970-A1 | KIT COMPRISING SILICONE COMPOUNDS AND A COSMETIC AND/OR DERMATOLOGICAL ACTIVE AGENT | L'OREAL (FR) | 2008-07-03 | — | — | US | disclosed |
| US-20070297999-A1 | KIT CONTAINING AN ACIDIC COMPOSITION AND A COMPOSITION BASED ON A HYDROXYALKYL UREA | L'OREAL (FR) | 2007-12-27 | — | — | US | disclosed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | disclosed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280040-A1 | SYNTHESIS AND PHARMACOKINETIC ACTIVITIES OF PULMODIL AND PULMODIL-1, TWO CHLOROPHENYLPIPERAZINE SALT DERIVATIVES | MCOLN1, AGTR1, CHRM1 | POLB 2150/4885ALDH1A1 1756/4885CYP3A4 215/4885 |
| US-20080159970-A1 | KIT COMPRISING SILICONE COMPOUNDS AND A COSMETIC AND/OR DERMATOLOGICAL ACTIVE AGENT | KRT18, CUTA, KIT | POLB 1374/4885ALDH1A1 3150/4885CYP3A4 4788/4885 |
| US-20190110977-A1 | PROCESS FOR TREATMENT OF KERATINOUS MATERIALS AND KIT FOR FORMULATION OF A COSMETIC PRODUCT | CUTA, KRT18, KIT | POLB 19/4885ALDH1A1 1955/4885CYP3A4 4412/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | POLB 3981/4885ALDH1A1 1550/4885CYP3A4 4148/4885 |
| US-20100280041-A1 | RHOKINASE-DEPENDENT INHIBITION ACTIVITY ON PULMONARY ARTERY ENDOTHELIUM DYSFUNCTION, MEDIAL WALL THICKNESS AND VASCULAR OBSTRUCTION OF PULMODIL AND PULMODIL-1 | ROCK1, MYLK, PTGIR | POLB 780/4885ALDH1A1 4001/4885CYP3A4 4031/4885 |
| US-20150359798-A1 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY | FABP1, LIPC, PLIN5 | POLB 644/4885ALDH1A1 371/4885CYP3A4 969/4885 |
| US-20150359901-A1 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY | FABP1, LIPC, PLIN5 | POLB 644/4885ALDH1A1 371/4885CYP3A4 969/4885 |
| US-20070297999-A1 | KIT CONTAINING AN ACIDIC COMPOSITION AND A COMPOSITION BASED ON A HYDROXYALKYL UREA | CUTA, PRKDC, UNG | POLB 72/4885ALDH1A1 1536/4885CYP3A4 4526/4885 |
| US-20150174157-A1 | INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY | NOS2, NOS3, NOS1 | POLB 238/4885ALDH1A1 476/4885CYP3A4 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.